About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Beta Amyloid PET/CT in Various Aβ-Related Disease | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGNCT06725706

Beta Amyloid PET/CT in Various Aβ-Related Disease

To evaluate the potential usefulness of 18F-92/AV45, 11C-PIB positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various Tau-related diseas...

Lead sponsor: Tianjin Medical University•3 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Ying Wang, MD

CONTACT

+8618702292537 macrossplusvoices@163.com

Li Cai, MD

CONTACT

+862260362190 xcl242004@126.com

Sponsors

Lead Sponsor

Tianjin Medical University

Collaborators

Tianjin Medical University General Hospital

Subjects with various Tau-related disease patients underwent 18F-92/AV45, 11C-PIB PET/CT either for an initial assessment or for recurrence detection. Lesions uptake was quantified by the maximum standard uptake value (SUVmax). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 18F-92/AV45, 11C-PIB PET/CT were calculated.

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Aβ PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Exclusion Criteria

•\- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Related studies

RECRUITINGPhase 3

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

NCT06563895 · Amyloidosis, Amyloid Cardiomyopathy, and more

RECRUITINGPhase 1/2

Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients

NCT07266116 · Systemic Light Chain Amyloidosis

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

NCT06465810 · Transthyretin Amyloidosis, ATTR-CM, and more

DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting

NCT07358078 · Transthyretin Amyloidosis With Cardiomyopathy

OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis

NCT06355934 · ATTR Amyloidosis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: June 4, 2025Terms

Trial snapshot

StatusRECRUITING

Phase—

Enrollment500

Start dateSep 2012

Last updatedJun 4, 2025

Condition

Amyloid Beta-Amyloid Neurodegenerative Diseases

Locations shown

The First Affiliated Hospital of University of Science and Technology of China

Hefei, Anhui

Chinese PLA General Hospital,

Beijing, Beijing Municipality

Tianjin Medical University General Hospital

Tianjin, Tianjin Municipality

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 4, 2025Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions